GSK 2857916

Drug Profile

GSK 2857916

Alternative Names: GSK-2857916; J6M0-mcMMAF

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple myeloma

Most Recent Events

  • 12 Dec 2017 Efficacy and adverse events data from the phase I DREAMM-1 trial in Multiple myeloma presented at the 59th annual meeting of the American Society for Haematology (ASH-2017)
  • 02 Nov 2017 GSK 2857916 receives Breakthrough Therapy status for Multiple myeloma (Second-line therapy or greater, Monotherapy) in USA
  • 02 Nov 2017 GSK 2857916 receives Orphan Drug status for Multiple myeloma in European Union before November 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top